Yaffa Beck and Weight - Free people check

(1 - 19 from 20

)

Obecure tests vertigo drug for obesity - UPI.com

www.upi.com

24 Jan — "There is a great unmet need for a safe and effective therapy that can control weight," said Yaffa Beck, chief executive officer of Obecure. › Health_News › › O...

Now a 'wonder' drug for safer weight loss - Times of Indiatimesofindia.indiatimes.com › ... › Health & Fitness

timesofindia.indiatimes.com

... support the potential of the drug as a breakthrough anti-obesity agent in women 50 years old or less," Dr Yaffa Beck, Obecure's CEO said.

Archives of weight watcher's blog from medicineworld.orgmedicineworld.org › weight-watch-news › Feb

medicineworld.org

... and support the potential of the drug as a breakthrough anti-obesity agent in women 50 years old or less, confirmed Dr. Yaffa Beck, Obecures CEO.

Dr. Joseph Albeck, MD – Newton, MA | Psychiatry - Doximity

www.doximity.com

Nir Barak, Yaffa Beck, Joseph H. Albeck> ;Journal of Clinical Psychopharmacology Jun 1; 16 citations. Betahistine decreases olanzapine-induced weight ... › ... › Massachusetts › Newton

New, Safer Wonder Drug Developed for Weight Loss - Medindia

www.medindia.net

... support the potential of the drug as a breakthrough anti-obesity agent in women 50 years old or less," Dr. Yaffa Beck, Obecure's CEO said.

New Drug Makes Weight Loss Safer, Study Suggests

www.sciencedaily.com

27 Sept — Yaffa Beck, Obecure's CEO. According to some estimates, obesity results in thousands of deaths a year and accounts for $117 billion in U.S › releases ›

New drug makes weight loss safer | EurekAlert! Science News

www.eurekalert.org

Dr. Nir Barak of TAU has adapted a well-known drug used to treat vertigo for a new purpose: to treat obesity without dangerous side effects.

Betahistine decreases olanzapine-induced weight PubMed

pubmed.ncbi.nlm.nih.gov

by N Barak · · Cited by 27 — Authors. Nir Barak , Yaffa Beck , Joseph H Albeck. Affiliations. 1 Obesity Clinic, Leumit Health Fund, Tel-Aviv, Israel . › ...

Biotechnology Advances | Vol 7, Issue 1, Pages (

www.sciencedirect.com

Method of producing high molecular weight sodium hyallronate by fermentation of streptococcus: Abraham Nimrod, Benjami Greenman, Dov Kanner, Moshe Landsberg, Yaffa Beck, Rehovot, Israel assigned to Bio-Technology General Corp Page 75 Download PDF

Betahistine-Associated Weight Loss and Improved Cognitive ...

read.qxmd.com

Nir Barak, Yaffa Beck, Joseph H Albeck Journal of Clinical Psychopharmacology 2016, 36 (3): Reducing antipsychotic-induced weight gain in ... › read › betahistine-associated-w...

New drug makes weight loss safer from medicineworld.org

medicineworld.org

... and support the potential of the drug as a breakthrough anti-obesity agent in women 50 years old or less, confirmed Dr. Yaffa Beck, Obecures CEO. › cancer › lead › new-drug-m...

US A - Method of producing high molecular weight sodium...

patents.google.com

A novel mutant microorganism Streptococcus zooepidemicus HA-116 ATCC , has been produced. The microorganism produces large amounts of high molecular...

Efficacy Study of Betahistine on Body Weight in Obese ...

clinicaltrials.gov

· Yaffa Beck, CEO, OBEcure Ltd. ClinicalTrials.gov Identifier: NCT Other Study ID Numbers: BET S ML5059 : First Posted: September 8, Key Record Dates: Last Update Posted: May 7, Last Verified: May 2009

Israeli researcher develops weight loss drug - ISRAEL21c

www.israel21c.org

Now, says Obecure CEO Dr. Yaffa Beck, studies of the drug will focus primarily on women under 50, since this approach seems to work best due to the presence of estrogen. Barak is a physician in Beilinson Hospital in Petah Tikva and an instructor at Tel Aviv University’s Sackler School of Medicine.

Betahistine Decreases Olanzapine-Induced Weight Gain and Somnolence...

scite.ai

Nir Barak, Yaffa Beck, Joseph H Albeck. Abstract: Olanzapine's efficacy in schizophrenia is attributed to antagonism of dopamine and serotonin receptors.

Obecure Initiates Phase II Weight Gain Prevention Study ...

pipelinereview.com

· “We believe that this is the first serious attempt to neutralize the weight gain associated with a variety of psychiatric medicines,” said Dr. Yaffa Beck, CEO of Obecure.

Obecure Recruits First Patient in Phase II Obesity Study | Small...

pipelinereview.com

“There is a great unmet need for a safe and effective therapy that can control weight,“ said Yaffa Beck, CEO of Obecure. “Our preliminary human study demonstrates that OBE101, comprised of betahistine, offers a promising new approach to meet that need.

Study to Examine the Effect of Betahistine on Body Weight Gain Due to...

clinicaltrials.gov

· Yaffa Beck: OBEcure Ltd. More Information. Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information. Layout table for additonal information; Responsible Party: OBEcure Ltd. ClinicalTrials.gov Identifier: NCT

The Effect of Betahistine on Body Weight in Obese Subjects - Full...

clinicaltrials.gov

The purpose of this study is to examine the effect that betahistine has on body weight in obese subjects ... Yaffa Beck, PhD: OBEcure Ltd. Study Chair: Ami Eyal, MD:

All web results to the name "Yaffa Beck"

Related search requests for Yaffa Beck

Felix Frolow
Marian Gorecki

Person "Beck" (7)
Forename "Yaffa" (91)
Name "Beck" (6480)

sorted by relevance / date

Advanced Search

Search name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Yaffa Beck and Weight Free People Check